Title: Imatinib—Milestones and Clinical Applications of Targeted Anticancer Drugs

First paragraph: content overview
Imatinib is a revolutionaryTargeted anticancer drugs, mainly used to treat chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST). Its core mechanism is to inhibitBCR-ABL fusion proteinandc-KIT receptor tyrosine kinase, blocking cancer cell proliferation signals. This article will start from the drug mechanism, indications, manufacturers and clinical effects, focusing on analyzing its medical value and limitations.

Paragraph 2: Drug Mechanism and R&D Background
Imatinib was developed by Novartis and approved by the FDA in 2001, becoming the firsttyrosine kinase inhibitorAnticancer drugs. By precisely targeting the BCR-ABL protein (the key to the pathogenesis of CML) and the c-KIT mutation (the main cause of GIST), it can significantly improve the efficacy and reduce the toxic and side effects of traditional chemotherapy. According to a study in the "New England Journal of Medicine", the 5-year survival rate of CML patients has increased from 50% to 90%, which is hailed as "a paradigm shift in cancer treatment" (Druker BJ, 2001).

Paragraph 3: Indications and clinical applications
In addition to CML and GIST, imatinib is approved forPh+ acute lymphoblastic leukemiaand other diseases. Clinical data show that the complete hematological remission rate of early-stage CML patients can reach 98%. However, some patients will develop drug resistance and need to be combined with second-generation drugs (such as dasatinib). China's "CSCO Guidelines" recommend it as a first-line drug, but liver function and blood pictures need to be monitored regularly.

Paragraph 4: Current situation of production and market
Major global manufacturers include originator Novartis (trade nameGleevec) and many generic drug manufacturers. Domestic generic drug manufacturers that have passed consistency evaluation are as follows:

Paragraph 5: Summary and Outlook
Imatinib has created a new era of targeted tumor therapy, but its high price and drug resistance problems still need to be overcome. With the coverage of medical insurance and the popularization of generic drugs, accessibility is gradually improving. Future research directions include combination drug regimens and cracking of drug resistance mechanisms to continue its vitality as an “anti-cancer star drug”.

Quote sources:
1. "New England Journal of Medicine": Druker BJ et al (2001) Clinical trial of imatinib in the treatment of CML
2. China's "CSCO Guidelines for the Diagnosis and Treatment of Chronic Myeloid Leukemia" (2022 Edition)
3. National Medical Products Administration generic drug approval data
4. Novartis Pharmaceuticals Gleevec® original research instructions